argenx SE

ARGX.BR·Brussels·Healthcare
Compare
815.00+26.20 (+3.32%)today
At close: Nov 4, 5:35 PM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close788.80
Open804.00
Day range796.80825.00
52-week range568.40925.00
Off day high−1.21%
Off 52-week high−11.89%
Volume170.17K
Avg. volume (3M)85.26K
Market cap51.25B
EPS (TTM)24.85
Forward P/E26.16
P/E ratio (TTM)32.80
Dividend yield—
Beta (5Y)-0.07
Shares outstanding62.89M
Short interest—
Earnings dateOct 22, 2026
Analyst target997.36
Profit margin31.73%

Against its peers

Compare in full ›
ARGX.BR ROIV 9995.HK 095700.KQ 6IB.F 2315.HK
Market cap 51.25B 27.61B 40.23B 94.14B 17.27B 19.07B
P/E (TTM) 32.8 — 6.1 — 123.8 45.2
Forward P/E 26.2 -27.5 46.7 — — 28.0
Price/book 6.8 6.5 3.8 — 6.2 6.6
Dividend yield — — — — — —
1-year change +9.04% +85.85% −19.94% −60.56% −1.76% +48.24%
Today +3.32% +6.08% +1.49% +0.73% +3.42% +2.09%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.

Latest news

All ARGX.BR news ›
The Manila Times·Positive

argenx to Present at Upcoming Investor Conferences

The Manila Times Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: -…

pharmaphorum·Negative

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2 billion acquisition of Forte Biosciences, will move into phase 3 development for coeliac disease after showing efficacy in a mid-stage trial. There are no FDA-approved…

The Killeen Daily Herald··2 outletsPositive

argenx Reports Third Quarter 2026 Financial Results and Provides Business Update

Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end; pursuing…

More from 1 other outlet

From the 4Search news index, newest first.

In the news

60mentions in 30 days
59with it in the headline
Mixedsentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 60 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance